Description of Additional Supplementary Files Supplementary Data 1 Reporting Summary Source data Source Data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any...
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). Article PubMed CAS Google Scholar Kaderbhai, C. et al. Antibiotic use does not appear to influence response to nivolumab. Anticancer Res. 37, 3195–3200 (2017). PubMed ...
a treatment comprising a therapeutically effective amount of an immunotherapy, preferably a checkpoint inhibitor, to a subject having a tumor in group 1;a treatment comprising a therapeutically effective amount of an immunotherapy, topoisomerase-I inhibitors, or platinum-based chemotherapy, optionally in ...
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 depicts various functions of mast cell agents. FIG. 2 depicts a three-drug combination. FIG. 3 depicts various therapeutic agents of the invention and their respective proposed mechanisms of action in monotherapy. FIG. 4 depicts the water maze recorded da...
This follows the WMO bulletin format for BUFR data (see [2]) andconstitutes a strictly hierarchical description of a radar image and is ideal for using a file-system hierarchy for organising the data. Or in other words: It is suggested to use the normal file-system for storing the single...
Cellular Immunotherapy for Prostate CancerTable 1. Description of randomized Phase III trials of sipuleucel-TStudyname Design Eligibility Treatment9901APolicy Number
Colucci et al., “Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide,” J Autoimmunity. 9:271-276 (1996). Sadelain et al., “Prevention of type I diabetes in NOD mice by adjuvant immunotherapy,” Diabetes. 39:583-589...